Synthesis, molecular characterisation, and in vivo study of platinum(IV) coordination compounds against B16 mouse melanoma tumours

[1] Barlin, G. B., & Fenn, M. D. (1986). A carbon-13 and proton nuclear magnetic resonance study of hydroxy- and mercaptonitropyridines and their N-, O-, and S-methyl derivatives and analogous compounds in dimethyl sulfoxide. Heterocycles, 24, 1301–1309.DOI:10.3987/R-1986-05-1301. http://dx.doi.org/10.3987/R-1986-05-130110.3987/R-1986-05-1301Search in Google Scholar

[2] Bülow, C., & Haas, K. (1909). Synthetische Versuche zur Darstellung von Derivaten des heterokondensierten, heterocyclischen 1.3-Triazo-7.0′-pyrimidins. Berichte der Deutschen Chemischen Gesellschaft, 42, 4638–4644.DOI:10.1002/cber.19090420468. http://dx.doi.org/10.1002/cber.1909042046810.1002/cber.19090420468Search in Google Scholar

[3] Burstyn, J. N., Heiger-Bernays, W. J., Cohen, S. M., & Lippard, S. J. (2000). Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independent. Nucleic Acids Research, 28, 4237–4243.DOI:10.1093/nar/28.21.4237. http://dx.doi.org/10.1093/nar/28.21.423710.1093/nar/28.21.4237Search in Google Scholar

[4] Chaney, S. G., Gibbons, G. R., Wyrick, S. D., & Podhasky, P. (1991). An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line. Cancer Research, 51, 969–973. Search in Google Scholar

[5] Dempke, W., Voigt, W., Grothey, A., Hill, B. T., & Schmoll, H.-J. (2000). Cisplatin resistance and oncogenes — a review. Anti-Cancer Drugs, 11, 225–236. http://dx.doi.org/10.1097/00001813-200004000-0000110.1097/00001813-200004000-00001Search in Google Scholar

[6] Dolman, R. C., Deacon, G. B., & Hambley, T. W. (2002). Studies of the binding of a series of platinum(IV) complexes to plasma proteins. Journal of Inorganic Biochemistry, 88, 260–267.DOI:10.1016/S0162-0134(01)00360-9. http://dx.doi.org/10.1016/S0162-0134(01)00360-910.1016/S0162-0134(01)00360-9Search in Google Scholar

[7] Drewa, T., Olszewska-Słonina, D., Woźniak, A., Styczyński, J., Drewa, G., Szłyk, E., Łakomska, I., Kobe, J., & Czajkowski, R. (2004). Influence of a novel platinum compound — cisdichloro(dimethylsulphoxide)(1-β-D-ribofuranosyl-1,2,4-triazolo-3-carboxyamide) platinum(II) — “Pt-rib-1” — on cell cycle and apoptosis in CLS91 and B16 mouse melanoma in vitro. Acta Poloniae Pharmaceutica — Drug Research, 61, 39–44 Search in Google Scholar

[8] Drewa, T., Woźniak, A., Drewa, G., Olszewska, D., Woźniak, B., Wysocki, M., Szłyk, E., & Łakomska, A. (2001). Effect of novel platinum complexes on survival rate of B16 and Cl S91 melanoma cells and oxidation stress in vitro. Medical Science Monitor, 7, 680–686. Search in Google Scholar

[9] Drewa, T., Woźniak, A., Olszewska, D., Szłyk, E., Łakomska, I., Mila-Kierzenkowska, C., & Czajkowski, R. (2001). The in vitro study of influence of four novel platinum compounds on rodent melanoma cells. Acta Poloniae Pharmaceutica — Drug Research, 58, 169–174. Search in Google Scholar

[10] Griffith, E. A. H., & Amma, E. L. (1979). Crystal structure and 48113 Cd n.m.r. spectrum of di-μ-chloro-dichlorobis-(6-mercaptopurine)diaquodicadmium (II). Journal of the Chemical Society, Chemical Communications, 1979, 1013–1014. DOI:10.1039/C39790001013. 10.1039/C39790001013Search in Google Scholar

[11] Grodzicki, A., Szłyk, E., Pazderski, L. Goliński, A., & Haasnoot, J. G. (1996). NMR properties of 5,7-disubstituted derivatives of 1,2,4-triazolo[1,5a]pyrimidines. Magnetic Resonance in Chemistry, 34, 725–727. DOI:10.1002/(SICI)1097-458X(199609)34:9〈725::AID-OMR939〉3.0.CO;2-Z. http://dx.doi.org/10.1002/(SICI)1097-458X(199609)34:9<725::AID-OMR939>3.0.CO;2-Z10.1002/(SICI)1097-458X(199609)34:9<725::AID-OMR939>3.0.CO;2-ZSearch in Google Scholar

[12] Gruber, B. M., Anuszewska, E. L., & Priebe, W. (2004). The effect of new anthracycline derivatives on the induction of apoptotic processes in human neoplastic cells. Folia Histochemica et Cytobiologica, 42, 127–130. Search in Google Scholar

[13] Hall, M. D., & Hambley, T. W. (2002). Platinum(IV) antitumor compounds: their bioinorganic chemistry. Coordination Chemistry Reviews, 232, 49–67.DOI:10.1016/S0010-8545(02)00026-7. http://dx.doi.org/10.1016/S0010-8545(02)00026-710.1016/S0010-8545(02)00026-7Search in Google Scholar

[14] Hartwig, J. F., & Lippard, S. J. (1992). DNA binding properties of [Pt(NH3)(C6H11NH2)Cl2], a metabolite of an orally active platinum anticancer drug. Journal of the American Chemical Society, 114, 5646–5654.DOI:10.1021/ja00040a026. http://dx.doi.org/10.1021/ja00040a02610.1021/ja00040a026Search in Google Scholar

[15] Kasparkova, J., Fojta, M., Farrell, N., & Brabec, V. (2004). Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Nucleic Acids Research, 32, 5546–5552.DOI:10.1093/nar/gkh896. http://dx.doi.org/10.1093/nar/gkh89610.1093/nar/gkh896Search in Google Scholar

[16] Katsaros, N., & Grigoratou, A. (1985). Platinum group metal complexes with 6-mercaptopurine and its riboside. Journal of Inorganic Biochemistry, 25, 131–140. DOI:10.1016/0162-0134(85)80021-0. http://dx.doi.org/10.1016/0162-0134(85)80021-010.1016/0162-0134(85)80021-0Search in Google Scholar

[17] Kaznica, A., Drewa, T., Lakomska, I., Ryta-Stamirowska, P., Debski, R., Styczynski, J., Drewa, G., & Szłyk, E. (2009). Influence of two Pt(IV) complexes on viability, apoptosis and cell cycle of B16 mouse melanoma tumors. Experimental Oncology, 31, 33–36. Search in Google Scholar

[18] Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer, 7, 573–584. DOI:10.1038/nrc2167. http://dx.doi.org/10.1038/nrc216710.1038/nrc2167Search in Google Scholar

[19] Kelland, L. R. (2000). Preclinical perspectives on platinum resistance. Drugs, 59, 1–8. http://dx.doi.org/10.2165/00003495-200059004-0000110.2165/00003495-200059004-00001Search in Google Scholar

[20] Khan, S. R. A., Huang, S., Shamsuddin, S., Inutsuka, S., Whitmire, K. H., Siddik, Z. H., & Khokhar, A. R. (2000). Synthesis, characterization and cytotoxicity of new platinum(IV) axial carboxylate complexes: crystal structure of potential antitumor agent [PtIV(trans-1R,2R-diaminocyclohexane) trans(acetate)2Cl2]. Bioorganic & Medicinal Chemistry, 8, 515–521. DOI:10.1016/S0968-0896(99)00313-2. http://dx.doi.org/10.1016/S0968-0896(99)00313-210.1016/S0968-0896(99)00313-2Search in Google Scholar

[21] Kim, K. M., Lee, Y.-A., Lee, S. S., & Sohn, Y. S. (1999). Facile synthesis and structural properties of (diamine)tetracarboxylatoplatinum(IV) complexes. Inorganica Chimica Acta, 292, 52–56. DOI:10.1016/S0020-1693(99)00169-3. http://dx.doi.org/10.1016/S0020-1693(99)00169-310.1016/S0020-1693(99)00169-3Search in Google Scholar

[22] Kurata, T., Tamura, T., Sasaki, Y., Fujii, H., Negoro, S., Fukuoka, M., & Saijo, N. (2000). Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichlorocyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Japanese Journal of Clinical Oncology, 30, 377–384. DOI:10.1093/jjco/hyd102. http://dx.doi.org/10.1093/jjco/hyd10210.1093/jjco/hyd102Search in Google Scholar PubMed

[23] Łakomska, I. (2009). Molecular structure and antitumor activity of platinum(II) complexes containing purine analogs. Inorganica Chimica Acta, 362, 669–681. DOI:10.1016/j.ica.2008.02.030. http://dx.doi.org/10.1016/j.ica.2008.02.03010.1016/j.ica.2008.02.030Search in Google Scholar

[24] Łakomska, I., Pazderski, L., Sitkowski, J., Kozerski, L., Pełczyńska, M., Nasulewicz, A., Opolski, A., & Szłyk, E. (2004). Multinuclear NMR spectroscopy and antiproliferative activity in vitro of platinum(II) and palladium(II) complexes with 6-mercaptopurine. Journal of Molecular Structure, 707, 241–247. DOI:10.1016/j.molstruc.2004.07.027. http://dx.doi.org/10.1016/j.molstruc.2004.07.02710.1016/j.molstruc.2004.07.027Search in Google Scholar

[25] Łakomska, I., Wojtczak, A., Sitkowski, J., Kozerski, L., & Szłyk, E. (2008). Platinum(IV) complexes with purine analogs. Studies of molecular structure and antiproliferative activity in vitro. Polyhedron, 27, 2765–2770. DOI:10.1016/j.poly.2008.05.032. 10.1016/j.poly.2008.05.032Search in Google Scholar

[26] Liedert, B., Materna, V., Schadendorf, D., Thomale, J., & Lage, H. (2003). Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. Journal of Investigative Dermatology, 121, 172–176. DOI:10.1046/j.1523-1747.2003.12313.x. http://dx.doi.org/10.1046/j.1523-1747.2003.12313.x10.1046/j.1523-1747.2003.12313.xSearch in Google Scholar PubMed

[27] Nakamoto, K. (1978). Infrared and Raman spectra of inorganic and coordination compounds. New York, NY, USA: Wiley. Search in Google Scholar

[28] Natile, G., & Coluccia, M. (2001). Current status of transplatinum compounds in cancer therapy. Coordination Chemistry Reviews, 216–217, 383–410. DOI:10.1016/S0010-8545(01)00315-0. http://dx.doi.org/10.1016/S0010-8545(01)00315-010.1016/S0010-8545(01)00315-0Search in Google Scholar

[29] Nitiss, J. L. (2002). A copper connection to the uptake of platinum anticancer drugs. Proceedings of the National Academy of Sciences of the United States of America, 99, 13963–13965. DOI:10.1073/pnas.232574299. http://dx.doi.org/10.1073/pnas.23257429910.1073/pnas.232574299Search in Google Scholar

[30] O’Dweyer, P. J., Stevenson, J. P., & Johnson, S. W. (1999). Clinical status of cisplatin, carboplatin, and other platinumbased antitumor drugs. In B. Lippert (Ed.), Cisplatin: chemistry and biochemistry of a leading anticancer drug (pp. 31–72). Weinheim, Germany: Wiley-VCH. Search in Google Scholar

[31] Presant, C. A., & Bartolucci, A. A. (1982). Prognostic factors in metastatic malignant melanoma. The southeastern cancer study group experience. Cancer, 49, 2192–2196. DOI:10.1002/1097-0142(19820515)49:10〈2192::AIDCNCR2820491035〉3.0.CO;2-R. http://dx.doi.org/10.1002/1097-0142(19820515)49:10<2192::AID-CNCR2820491035>3.0.CO;2-R10.1002/1097-0142(19820515)49:10<2192::AID-CNCR2820491035>3.0.CO;2-RSearch in Google Scholar

[32] Reedijk, J. (2009). Platinum anticancer coordination compounds: Study of DNA binding inspires new drug design. European Journal of Inorganic Chemistry, 2009, 1303–1312. DOI:10.1002/ejic.200900054. http://dx.doi.org/10.1002/ejic.20090005410.1002/ejic.200900054Search in Google Scholar

[33] Reedijk, J. (2008). Metal-ligand exchange kinetics in platinum and ruthenium complexes. Platinum Metals Review, 52, 2–11. DOI:10.1595/147106708X255987. http://dx.doi.org/10.1595/147106708X25598710.1595/147106708X255987Search in Google Scholar

[34] Sabo, T. J., Đinović, V. M., Kaluđerović, G. N., Stanojković, T. P., Bogdanović, G. A., & Juranić Z. D. (2005). Syntheses and activity of some platinum(IV) complexes with N-methyl derivate of glycine and halogeno ligands against HeLa, K562 cell lines and human PBMC. Inorganica Chimica Acta, 358, 2239–2245. DOI:10.1016/j.ica.2005.01.007. http://dx.doi.org/10.1016/j.ica.2005.01.00710.1016/j.ica.2005.01.007Search in Google Scholar

[35] Shamsuddin, S., Santillan, C. C., Stark, J. L., Whitmire, K. H., Siddik, Z. H., & Khokhar, A. R. (1998). Synthesis, characterization, and antitumor activity of new platinum(IV) trans-carboxylate complexes: Crystal structure of [Pt(cis-1,4-DACH)trans-(acetate)2Cl2]. Journal of Inorganic Biochemistry, 71, 29–35. DOI:10.1016/S0162-0134(98)10029-6. http://dx.doi.org/10.1016/S0162-0134(98)10029-610.1016/S0162-0134(98)10029-6Search in Google Scholar

[36] Shamsuddin, S., Takahashi, I., Siddik, Z. H., & Khokhar, A. R. (1996). Synthesis, characterization, and antitumor activity of a series of novel cisplatin analogs with cis-1,4-diaminocyclohexane as nonleaving amine group. Journal of Inorganic Biochemistry, 61, 291–301. DOI:10.1016/0162-0134(95)00084-4. http://dx.doi.org/10.1016/0162-0134(95)00084-410.1016/0162-0134(95)00084-4Search in Google Scholar

[37] Silverstein, R. M., & Webster, F. X. (1998). Spectrometric identification of organic compounds (6th ed.). New York, NY, USA: Wiley. Search in Google Scholar

[38] Smith, J. A., Ngo, H., Martin, M. C., & Wolf, J. K. (2005). An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecologic Ongology, 98, 141–145. DOI:10.1016/j.ygyno.2005.02.006. http://dx.doi.org/10.1016/j.ygyno.2005.02.00610.1016/j.ygyno.2005.02.006Search in Google Scholar

[39] Song, R., Park, S. Y., Kim, Y.-S., Kim, Y., Kim, S.-J, Ahn, B. T., & Sohn, Y. S. (2003). Synthesis and cytotoxicity of new platinum(IV) complexes of mixed carboxylates. Journal of Inorganic Biochemistry, 96, 339–345. DOI:10.1016/S0162-0134(03)00149-1. http://dx.doi.org/10.1016/S0162-0134(03)00149-110.1016/S0162-0134(03)00149-1Search in Google Scholar

[40] Woźniak, K., & Błasiak, J. (2002). Recognition and repair of DNA-cisplatin adducts. Acta Biochimica Polonica, 49, 583–596. 10.18388/abp.2002_3768Search in Google Scholar